REFERENCES
- Crowley, P.; Martini, L. Drug–excipient interactions.Pharm. Technol. Eur. 2001, 13 (3), 26–34., [CSA]
- Kontny, M.J. Distribution of water in pharmaceutical systems.Drug Dev. Ind. Pharm. 1988, 14 (14), 1991–2027., [CSA]
- Florence, A.T.; Attwood, D. Physicochemical Principles of Pharmacy, 3rd Ed.; Macmillan Education Ltd.: London, 1998; 136–139.
- Villalobos-Henández, J.R.; Villafuerte-Robles, L. Effect of carrier excipient and processing on stability of indorenate hydrochloride/excipients mixtures.Pharm. Dev. Technol. 2001, 6 (4), 551–561., [CSA], [CROSSREF]
- , International Conference on Harmonization. Stability Testing of New Drugs and Products (revised guideline); Adopted by CPMP, November 2000, issued as CPMP/ICH/2736/99.
- Monkhouse, D.C.; Maderich, A. Whither compatibility testing?Drug Dev. Ind. Pharm. 1989, 15 (13), 2115–2130.
- Leuenberger, H. A factorial design for compatibility studies in preformulation work.Pharm. Acta Helv. 1975, 50 (4), 88–91., [PUBMED], [INFOTRIEVE], [CSA]
- Lewis, G.A.; Mathieu, D.; Phan-Tan-Luu, R. Pharmaceutical Experimental Design; Marcel Dekker Inc.: New York, 1999; 54–61.
- Dürig, T.; Fassihi, A.R. Identification of stabilizing and destabilizing effects of excipient-drug interactions in solid dosage form design.Int. J. Pharm. 1993, 97, 161–170., [CSA], [CROSSREF]
- Serajuddin, A.T.M.; Thakur, A.B.; Ghoshal, R.N.; Fakes, M.G.; Ranadive, S.A.; Morris, K.R.; Sailesh, A.V. Selection of solid dosage form composition through drug-excipient compatibility testing.J. Pharm. Sci. 1999, 88 (7), 696–704., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sims, J.L.; Carreira, J.A.; Carrier, D.J.; Crabtree, S.R.; Eason, L.; Hancock, St.A.; Simcox, C.E. A new approach to accelerated drug-excipient compatibility testing.Pharm. Dev. Technol. 2003, 8 (2), 119–126., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Martinez, L.; Uribarri, E.; Laguna, A. Characterization and compatibility studies between policosanol, a new hypocholesterolemic drug, and tablet excipients using differential scanning calorimetry.Arch. Pharm. Pharm. Med. Chem. 1999, 332, 439–441., [CSA], [CROSSREF]
- Logonathan, V.; Senthilkumar, S.; Reddy, M.; Sivaparasadha, V.; Sreekant, N.; Ubaidulla, U.; Manimaran, S. Compatibility studies between oflaxacin and tablet excipients through differential scanning calorimetry (DSC).Int. J. Pharm. Excip. 2003, 90–94., [CSA]
- Ceschel, G.C.; Badiello, R.; Ronchi, C.; Maffei, P. Degradation of components in drug formulations: a comparison between HPLC and DSC methods.J. Pharm. Biomed. Anal. 2003, 32, 1067–1072., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- McDaid, F.M.; Barker, S.A.; Fitzpatrick, S.; Petts, C.R.; Craig, D.Q.M. Further investigations into the use of high sensitivity differential scanning calorimetry as a means of predicting drug–excipient interactions.Int. J. Pharm. 2003, 252, 235–240., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Selzer, T.; Radau, M.; Kreuter, J. Use of isothermal heat conduction microcalorimetry to evaluate stability and excipient compatibility of a solid drug.Int. J. Pharm. 1998, 171, 227–241., [CSA], [CROSSREF]
- Schmitt, E.A.; Peck, K.; Sun, Y.; Geoffroy, J.M. Rapid, practical and predictive excipient compatibility screening using isothermal microcalorimetry.Thermochim. Acta 2001, 380 (2), 175–184., [CSA], [CROSSREF]
- Hartauer, K.J.; Guillory, J.K. A comparison of diffuse reflectance FT-IR spectroscopy and DSC in the characterization of drug-excipient interaction.Drug Dev. Ind. Pharm. 1991, 17, 617–630., [CSA]
- Mroso, P.V.; Wan Po, A.L.; Irwin, W.J. Solid-state stability of aspirin in the presence of excipients: kinetic interpretation, modeling and prediction.J. Pharm. Sci. 1982, 71 (10), 1096–1101., [PUBMED], [INFOTRIEVE], [CSA]
- Byrn, S.R.; Xu, W.; Newman, A.W. Chemical reactivity in solid-state pharmaceuticals: formulation implications.Adv. Drug Deliv. Rev. 2001, 48, 115–136., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Wirth, D.D.; Baertschi, St.W.; Johnson, R.A.; Maple, St.R.; Miller, M.S.; Hallenbeck, D.K.; Gregg, St.M. Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine.J. Pharm. Sci. 1998, 87 (1), 31–39., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Van Doren, A. A design for drug-excipient interaction studies.Drug Dev. Ind. Pharm. 1983, 9, 43–55., [CSA]
- Gardner, C.R.; Almarsson, O.; Chen, H.; Morissette, S.; Peterson, M.; Zhang, Z.; Wang, S.; Lemmo, A.; Gonzales-Zugasti, J.; Monagle, J.; Marchionna, J.; Ellis, St.; McNutley, Ch.; Johnson, A.; Levinson, D.; Cima, M. Application of high throughput technologies to drug substance and drug product development.Comput. Chem. Eng. 2004, 28, 943–953., [CSA], [CROSSREF]